Current Report Filing (8-k)

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): December 12, 2019

 

THERAPEUTIC SOLUTONS INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada		000-54554		45-1226465
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification Number)

 

4093 Oceanside Boulevard, Suite B

Oceanside, California 92056

(Address of Principal Executive Offices and Zip Code)

[phone]

(Issuer's telephone number)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

.

[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

.

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

.

[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

.

[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

 

 

Item 8.01 Other Events.

 

On December 09, 2019, Therapeutic Solutions International, Inc. entered into a Sales Agreement (the “Agreement”) with Tiva Bio, who has agreed to purchase a minimum of $500,000.00 worth of nutraceuticals from Therapeutic Solutions International, Inc. at an agreed upon discount. The Agreement provides three scaled discounts based on sales milestones of $500,000, $750,000 and $1,500,000.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit Index

 

(10.1)	Sales Agreement between Therapeutic Solutions International, Inc., and Tiva Bio.
(99)	Press release dated December 12, 2019, issued by Therapeutic Solutions International, Inc.

---

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 12, 2019

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

 

By: /s/ Timothy Dixon

Timothy Dixon

Chief Executive Officer